19:53 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Endocyte stops enrollment in Phase Ia/Ib solid tumor trial of EC1456

Endocyte Inc. (NASDAQ:ECYT) will stop enrollment in the Phase Ib portion of an open-label, U.S. Phase Ia/Ib trial of twice-weekly 6 mg/m 2 EC1456 in up to 40 folate receptor-positive non-small cell lung cancer (NSCLC)...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

EC1456: Phase I data

Data from 16 evaluable patients with metastatic or locally advanced solid tumors who failed to respond to standard therapy if available in the first part of an open-label, dose-escalation, U.S. Phase I trial showed that...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Folcepri etarfolatide regulatory update

Merck withdrew an MAA from EMA seeking conditional approval of Folcepri etarfolatide, a companion imaging diagnostic for Endocyte's Vynfinit vintafolide, to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. The companies...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Neocepri iV folic acid regulatory update

Endocyte and partner Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) announced the withdrawal of an MAA from EMA seeking conditional approval of Neocepri IV folic acid, a companion imaging diagnostic for Endocyte's Vynfinit vintafolide,...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Vynfinit vintafolide regulatory update

Merck withdrew an MAA from EMA seeking conditional approval of Vynfinit vintafolide to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. The pharma and partner Endocyte made the decision based on...
07:00 , May 5, 2014 |  BC Week In Review  |  Clinical News

Vynfinit vintafolide: Phase III halted

Merck and Endocyte suspended the double-blind, placebo-controlled, international Phase III PROCEED trial evaluating Vynfinit in combination with doxorubicin to treat folate receptor-positive platinum-resistant ovarian cancer after an independent DSMB recommended the trial be stopped early...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Folcepri etarfolatide regulatory update

EMA's CHMP issued a positive opinion recommending conditional approval of Folcepri etarfolatide, a companion imaging diagnostic for Endocyte's Vynfinit vintafolide, to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. Folcepri, a...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Neocepri IV folic acid regulatory update

EMA's CHMP issued a positive opinion recommending conditional approval of Neocepri IV folic acid, a companion imaging diagnostic for Endocyte's Vynfinit vintafolide, to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin....
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Vynfinit vintafolide regulatory update

EMA's CHMP issued a positive opinion recommending conditional approval of Vynfinit vintafolide to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin. Vynfinit is indicated for adults who express the folate receptor...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Vynfinit vintafolide: Phase IIb data

The open-label, international Phase IIb TARGET trial in 199 patients with stage IIIb or IV NSCLC showed that Vynfinit plus docetaxel met the primary endpoint of improving PFS vs. docetaxel alone (HR=0.75; p=0.0696). Endocyte said...